DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma.
DARS2
Glycolysis
Lung adenocarcinoma
PET/CT
SUVmax
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
26 08 2023
26 08 2023
Historique:
received:
21
05
2023
accepted:
19
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
This study investigated the correlation between the expression of DARS2 and metabolic parameters of This study used genomics and proteomics to analyze the difference in DARS2 expression between LUAD samples and control samples. An analysis of 62 patients with LUAD who underwent DARS2 expression was significantly higher in LUAD samples than in control samples (p < 0.001). DARS2 has high specificity (98.4%) and sensitivity (95.2%) in the diagnosis of LUAD. DARS2 expression was positively correlated with SUVmax, SUVmean, and TLG (p < 0.001). At the same time, the sensitivity and specificity of SUVmax in predicting DARS2 overexpression in LUAD were 88.9% and 65.9%, respectively. In vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1. Overexpression of DARS2 is associated with metabolic parameters on
Sections du résumé
BACKGROUND
This study investigated the correlation between the expression of DARS2 and metabolic parameters of
METHODS
This study used genomics and proteomics to analyze the difference in DARS2 expression between LUAD samples and control samples. An analysis of 62 patients with LUAD who underwent
RESULTS
DARS2 expression was significantly higher in LUAD samples than in control samples (p < 0.001). DARS2 has high specificity (98.4%) and sensitivity (95.2%) in the diagnosis of LUAD. DARS2 expression was positively correlated with SUVmax, SUVmean, and TLG (p < 0.001). At the same time, the sensitivity and specificity of SUVmax in predicting DARS2 overexpression in LUAD were 88.9% and 65.9%, respectively. In vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.
CONCLUSIONS
Overexpression of DARS2 is associated with metabolic parameters on
Identifiants
pubmed: 37626419
doi: 10.1186/s12967-023-04454-3
pii: 10.1186/s12967-023-04454-3
pmc: PMC10463715
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
DARS2 protein, human
EC 6.1.1.12
Aspartate-tRNA Ligase
EC 6.1.1.12
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
574Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54.
pubmed: 34273294
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.
pubmed: 29364287
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:1–20.
Seguin L, Durandy M, Feral CC. Lung adenocarcinoma tumor origin: a guide for personalized medicine. Cancers. 2022;14:1759.
pubmed: 35406531
pmcid: 8996976
Gao S, Li N, Wang S, Zhang F, Wei W, Li N, et al. Lung cancer in People’s Republic of China. J Thorac Oncol. 2020;15:1567–76.
pubmed: 32981600
Scheper GC, van der Klok T, van Andel RJ, van Berkel CGM, Sissler M, Smet J, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007;39:534–9.
pubmed: 17384640
Aradjanski M, Dogan SA, Lotter S, Wang S, Hermans S, Wibom R, et al. DARS2 protects against neuroinflammation and apoptotic neuronal loss, but is dispensable for myelin producing cells. Hum Mol Genet. 2017;26:4181–9.
pubmed: 28985337
Isohanni P, Linnankivi T, Buzkova J, Lonnqvist T, Pihko H, Valanne L, et al. DARS2 mutations in mitochondrial leucoencephalopathy and multiple sclerosis. J Med Genet. 2010;47:66–70.
pubmed: 19592391
Zhang X, Dong W, Zhang J, Liu W, Yin J, Shi D, et al. A novel mitochondrial-related nuclear gene signature predicts overall survival of lung adenocarcinoma patients. Front Cell Dev Biol. 2021;9: 740487.
pubmed: 34760888
pmcid: 8573348
Yang L, Zhang R, Guo G, Wang G, Wen Y, Lin Y, et al. Development and validation of a prediction model for lung adenocarcinoma based on RNA-binding protein. Ann Transl Med. 2021;9:474–474.
pubmed: 33850871
pmcid: 8039651
Sun N, Chu J, Hu W, Chen X, Yi N, Shen Y. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model. Sci Rep. 2022;12:27.
pubmed: 34996932
pmcid: 8741994
Guo C, Shao T, Jiang X, Wei D, Wang Z, Li M, et al. Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinoma. Am J Transl Res. 2020;12:7160–73.
pubmed: 33312357
pmcid: 7724358
Wu Y, Liu Z, Wei X, Feng H, Hu B, Liu B, et al. Identification of the functions and prognostic values of RNA binding proteins in bladder cancer. Front Genet. 2021;12: 574196.
pubmed: 34239534
pmcid: 8258248
Chen F, Wang Q, Zhou Y. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer. BMC Cancer. 2021;21:244.
pubmed: 33685397
pmcid: 7938493
Qin X, Li C, Guo T, Chen J, Wang H-T, Wang Y-T, et al. Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway. J Exp Clin Cancer Res. 2017;36:148.
pubmed: 29052520
pmcid: 5649064
Liu X-S, Zeng J, Zhang Y-H, Zhang Y, Gao Y, Liu C, et al. DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma. Am J Cancer Res. 2023;13:818–34.
pubmed: 37034224
pmcid: 10077054
Pan C, Li B, Simon MC. Moonlighting functions of metabolic enzymes and metabolites in cancer. Mol Cell. 2021;81:3760–74.
pubmed: 34547237
Chung HW, Lee KY, Kim HJ, Kim WS, So Y. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2014;140:89–98.
pubmed: 24194352
Jadvar H, Alavi A, Gambhir SS.
pubmed: 19837767
Xia H, Chen J, Gao H, Kong SN, Deivasigamani A, Shi M, et al. Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:787–97.
pubmed: 31832727
Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021;13:4184.
pubmed: 34439338
pmcid: 8394807
Kudura K, Ritz N, Kutzker T, Hoffmann MHK, Templeton AJ, Foerster R, et al. Predictive value of baseline FDG-PET/CT for the durable response to immune checkpoint inhibition in NSCLC patients using the morphological and metabolic features of primary tumors. Cancers. 2022;14:6095.
pubmed: 36551581
pmcid: 9776660
Tomczak K, Czerwińska P, Wiznerowicz M. Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Współczesna Onkologia. 2015;1A:68–77.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2012;41:D991–5.
pubmed: 23193258
pmcid: 3531084
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.
pubmed: 25605792
pmcid: 4402510
Liu X-S, Yuan L-L, Gao Y, Zhou L-M, Yang J-W, Pei Z-J. Overexpression of METTL3 associated with the metabolic status on
pubmed: 32626532
pmcid: 7330681
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S, et al. Transcriptional regulation of the warburg effect in cancer by SIX1. Cancer Cell. 2018;33:368-385.e7.
pubmed: 29455928
Gao Y, Yuan L, Zeng J, Li F, Li X, Tan F, et al. eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma. J Transl Med. 2022;20:303.
pubmed: 35794622
pmcid: 9258187
Zhang H, Xing M, Guo J, Zhao J, Chen X, Jiang Z, et al. Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway. Cancer Cell Int. 2019;19:313.
pubmed: 31787850
pmcid: 6880520
Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS J Integr Biol. 2012;16:284–7.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
Su X, Yang Y, Guo C, Zhang R, Sun S, Wang Y, et al. NOX4-derived ROS mediates TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition through the PI3K/AKT/HIF-1α pathway in glioblastoma. Oxid Med Cell Longev. 2021;2021:1–30.
Koc ZC, Sollars VE, Bou Zgheib N, Rankin GO, Koc EC. Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer. Front Oncol. 2023;13:1129352.
pubmed: 36937395
pmcid: 10014927
Jiang Y, You J, Wu C, Kang Y, Chen F, Chen L, et al. High expression of DARS2 indicates poor prognosis in lung adenocarcinoma. J Clin Lab Anal. 2022;36: e24691.
pubmed: 36085578
pmcid: 9550967
Jin X, Zhang H, Sui Q, Li M, Liang J, Hu Z, et al. Identification and validation of the mitochondrial function related hub genes by unsupervised machine learning and multi-omics analyses in lung adenocarcinoma. Heliyon. 2022;8: e11966.
pubmed: 36506395
pmcid: 9732315
Ucer O, Kocaman N. New candidates in the differential diagnosis of malignant mesothelioma from benign mesothelial hyperplasia and adenocarcinoma; DARS2 and suprabasin. Tissue Cell. 2022;79: 101920.
pubmed: 36182716
Moon SH, Kim J, Joung J-G, Cha H, Park W-Y, Ahn JS, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446–54.
pubmed: 30145701
Guo M, Peng Y, Gao A, Du C, Herman JG. Epigenetic heterogeneity in cancer. Biomark Res. 2019;7:23.
pubmed: 31695915
pmcid: 6824025
Kishimoto M, Iwano S, Ito S, Kato K, Ito R, Naganawa S. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT. Lung Cancer. 2014;86:180–4.
pubmed: 25263854
Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61.
pubmed: 27251642
Dondi F, Albano D, Bellini P, Cerudelli E, Treglia G, Bertagna F. Prognostic role of baseline 18F-FDG pet/CT in stage I and stage ii non-small cell lung cancer. Clin Imaging. 2023;94:71–8.
pubmed: 36495848
Chandel NS. Glycolysis. Cold Spring Harb Perspect Biol. 2021;13: a040535.
pubmed: 33941515
pmcid: 8091952
Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.
pubmed: 21985671
Chelakkot C, Chelakkot VS, Shin Y, Song K. Modulating glycolysis to improve cancer therapy. IJMS. 2023;24:2606.
pubmed: 36768924
pmcid: 9916680
Passarella S, Schurr A, Portincasa P. Mitochondrial transport in glycolysis and gluconeogenesis: achievements and perspectives. IJMS. 2021;22:12620.
pubmed: 34884425
pmcid: 8657705
Fine AS, Nemeth CL, Kaufman ML, Fatemi A. Mitochondrial aminoacyl-tRNA synthetase disorders: an emerging group of developmental disorders of myelination. J Neurodev Disord. 2019;11:29.
pubmed: 31839000
pmcid: 6913031
Xia H, Zhang Z, Yuan J, Niu Q. The lncRNA PVT1 promotes invasive growth of lung adenocarcinoma cells by targeting miR-378c to regulate SLC2A1 expression. Hum Cell. 2021;34:201–10.
pubmed: 32960438
Han J, Deng X, Sun R, Luo M, Liang M, Gu B, et al. GPI is a prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Front Oncol. 2021;11: 752642.
pubmed: 34912709
pmcid: 8666546
Fu H, Gao H, Qi X, Zhao L, Wu D, Bai Y, et al. Aldolase A promotes proliferation and G
Huang K, Liang Q, Zhou Y, Jiang L, Gu W, Luo M, et al. A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small-cell lung cancer. Cell Metab. 2019;30:1107-1119.e8.
pubmed: 31607564